
Opinion|Videos|August 21, 2024
Coexisting Cardiometabolic Conditions and Hypercortisolism
Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do you interpret the finding that one-third of patients on three or more hypertension medications also had hypercortisolism?
- You presented the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ at the last ADA scientific session. Can you briefly explain the linkage between hypercortisolism and diabetes?
- How does hypercortisolism physiologically impact the management of T2D?
- Why is it important to address hypercortisolism? What are the consequences of untreated hypercortisolism in patients with diabetes?
- What are the clinical implications of this data? How does it inform or change the way we manage patients with difficult-to-control diabetes?
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial
2
Sutezolid Shows Promise as Safer Oxazolidinone in Novel 4-Month TB Regimen
3
Tezepelumab Reduces Severe Asthma Exacerbations by 70% in Phase 4 PASSAGE
4
twiist AID System Improves HbA1c, Time in Range in Insulin-Treated Type 2 Diabetes
5


























































